Vor Biopharma logo

Vor BiopharmaNASDAQ: VOR

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

05 February 2021

Next earnings report:

20 March 2025

Last dividends:

N/A

Next dividends:

N/A
$54.94 M
-89%vs. 3y high
36%vs. sector
-vs. 3y high
-vs. sector
-76%vs. 3y high
34%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | Fri, 22 Nov 2024 00:39:41 GMT
$0.80$0.00(0.00%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

VOR Latest News

New Clinical Data Validates Vor Bio's Approach of Using Shielded Transplants to Deliver Targeted Therapies
globenewswire.com05 September 2024 Sentiment: POSITIVE

CAMBRIDGE, Mass., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced new clinical data from its ongoing Phase 1/2 VBP101 study of patients with relapsed/refractory AML receiving trem-cel followed by Mylotarg™. The data demonstrated reliable engraftment, shielding from Mylotarg on-target toxicity, a broadened Mylotarg therapeutic window, and early evidence of patient benefit.

Vor Bio to Participate in Upcoming Investor Conferences
globenewswire.com28 August 2024 Sentiment: POSITIVE

CAMBRIDGE, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming investor conferences:

Why You Shouldn't Bet Against Vor Biopharma (VOR) Stock
Zacks Investment Research04 April 2024 Sentiment: POSITIVE

Vor Biopharma (VOR) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Vor Bio to Participate in Upcoming Investor Conferences
GlobeNewsWire01 April 2024 Sentiment: NEUTRAL

CAMBRIDGE, Mass., April 01, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming investor conferences:

Vor Bio (VOR) Up on Positive Update From AML Cell Therapy Study
Zacks Investment Research19 January 2024 Sentiment: POSITIVE

Vor Bio (VOR) stock gains after dosing the first patient in its phase I/II study of novel cell therapy, VCAR33 (Allogenic), to treat AML. The company extends its cash runway into the second half of 2025.

Vor Bio to Participate in Upcoming Investor Conferences
GlobeNewsWire25 September 2023 Sentiment: NEGATIVE

CAMBRIDGE, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming investor conferences:

How Much Upside is Left in Vor Biopharma Inc. (VOR)? Wall Street Analysts Think 172.06%
Zacks Investment Research28 March 2023 Sentiment: POSITIVE

The mean of analysts' price targets for Vor Biopharma Inc. (VOR) points to a 172.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Vor Biopharma: Very Interesting Idea For Improving CAR-T Through Stem Cells
Seeking Alpha27 March 2023 Sentiment: POSITIVE

Vor Biopharma Inc. is the brainchild of Dr. Siddhartha Mukherjee. Its core idea is to make CAR-Ts safer by using stem cells.

Vor Bio Announces Q4 And FY 2022 Results
Pulse224 March 2023 Sentiment: POSITIVE

Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, reported its financial results for the three-month period and full year that ended December 31, 2022, and provided a business update. The post Vor Bio Announces Q4 And FY 2022 Results appeared first on Pulse 2.0.

What type of business is Vor Biopharma?

Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies. The company is also developing Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, which are under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system that is under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, which are under preclinical studies for the treatment of AML. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

What sector is Vor Biopharma in?

Vor Biopharma is in the Healthcare sector

What industry is Vor Biopharma in?

Vor Biopharma is in the Biotechnology industry

What country is Vor Biopharma from?

Vor Biopharma is headquartered in United States

When did Vor Biopharma go public?

Vor Biopharma initial public offering (IPO) was on 05 February 2021

What is Vor Biopharma website?

https://www.vorbio.com

Is Vor Biopharma in the S&P 500?

No, Vor Biopharma is not included in the S&P 500 index

Is Vor Biopharma in the NASDAQ 100?

No, Vor Biopharma is not included in the NASDAQ 100 index

Is Vor Biopharma in the Dow Jones?

No, Vor Biopharma is not included in the Dow Jones index

When was Vor Biopharma the previous earnings report?

No data

When does Vor Biopharma earnings report?

The next expected earnings date for Vor Biopharma is 20 March 2025